The NHS in England will be the first health system in the world to roll-out a ‘trojan horse’ targeted therapy for blood cancer patients which could halt the disease’s progression by nearly three times as long as existing treatments.
Around 1,500 patients a year with multiple myeloma – an incurable cancer of the bone marrow – could now be offered belantamab mafodotin on the NHS in England, after it was approved by the National Institute for Health and Care Excellence (NICE) yesterday [12 June].
The drug will be offered to eligible patients whose cancer has progressed or not responded to first-line treatment with another drug, lenalidomide…
